Broadfin Capital Picked Up Alphatec Holdings Inc. (NASDAQ:ATEC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alphatec Holdings Inc. (NASDAQ:ATEC) reported that has picked up 1,164,618 of common stock as of 2017-03-29.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 1,164,618 representing less than 9.99% stake in the company.
For those not familiar with the company, Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.
A glance at Alphatec Holdings Inc. (NASDAQ:ATEC)’s key stats reveals a current market capitalization of 21.89 Million based on 8.81 Million shares outstanding and a price at last close of $2.40 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-16, Cross picked up 15,000 at a purchase price of $4.25. This brings their total holding to 65,443 as of the date of the filing.
On the sell side, the most recent transaction saw Foster unload 1,033 shares at a sale price of $5.25. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alphatec Holdings Inc. (NASDAQ:ATEC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulmatrix Inc. (NASDAQ:PULM) reported that 5am Ventures Llc. has picked up 251,188 of common stock as of 2017-03-29.
The acquisition brings the aggregate amount owned by 5am Ventures Llc. to a total of 251,188 representing less than 1.41% stake in the company.
For those not familiar with the company, Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
A glance at Pulmatrix Inc. (NASDAQ:PULM)’s key stats reveals a current market capitalization of 53.11 Million based on 17.83 Million shares outstanding and a price at last close of $3.23 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-15, Mcguire picked up 1,392 at a purchase price of $6.88. This brings their total holding to 52,722 as of the date of the filing.
On the sell side, the most recent transaction saw Oculus unload 922,500 shares at a sale price of $2.75. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulmatrix Inc. (NASDAQ:PULM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) reported that Longboard Capital Advisors, Llc. has picked up 1,312,000 of common stock as of 2017-03-29.
The acquisition brings the aggregate amount owned by Longboard Capital Advisors, Llc. to a total of 1,312,000 representing a 6.58% stake in the company.
For those not familiar with the company, Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
A glance at Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY)’s key stats reveals a current market capitalization of 85.48 Million based on 19.94 Million shares outstanding and a price at last close of $3.85 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-19, Lindstrom picked up 100,000 at a purchase price of $1.79. This brings their total holding to 100,000 as of the date of the filing.
On the sell side, the most recent transaction saw Miloni unload 110,000 shares at a sale price of $8.00. This brings their total holding to 468,576.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) reported that Baker Bros. Advisors has picked up 10,934,154 of common stock as of 2017-03-27.
The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 10,934,154 representing a 46.7% stake in the company
For those not familiar with the company, Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.
A glance at Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s key stats reveals a current market capitalization of 375.12 Million based on 23.42 Million shares outstanding and a price at last close of $15.89 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-09, Baker picked up 32,051 at a purchase price of $17.76. This brings their total holding to 9,764,459 as of the date of the filing.
On the sell side, the most recent transaction saw Mackenzie unload 35,887 shares at a sale price of $18.67. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
OrbiMed Advisors Picked Viewray Inc. (NASDAQ:VRAY) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Viewray Inc. (NASDAQ:VRAY) reported that OrbiMed Advisors has picked up 9,866,102 of common stock as of 2017-03-21.
The acquisition brings the aggregate amount owned by OrbiMed Advisors to a total of 9,866,102 representing a 17.7% stake in the company.
For those not familiar with the company, ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
A glance at Viewray Inc. (NASDAQ:VRAY)’s key stats reveals a current market capitalization of 377.33 million based on 38.23 Million shares outstanding and a price at last close of $7.16 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-18, Bansal picked up 62,597 at a purchase price of $3.17. This brings their total holding to 70,104 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Viewray Inc. (NASDAQ:VRAY) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Taiwan Fund Inc (NYSE:TWN) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Taiwan Fund Inc (NYSE:TWN) reported that Lazard Asset Management Llc. has picked up 1,729,646 of common stock as of 2017-03-20.
The acquisition brings the aggregate amount owned by Lazard Asset Management Llc. to a total of 1,729,646 representing a 21.03% stake in the company.
For those not familiar with the company, The Taiwan Fund, Inc. is a diversified, closed-end management investment company. The Fund’s investment objective is to seek long-term capital appreciation through investment primarily in equity securities listed on the Taiwan Stock Exchange (TSE) in the Republic of China (ROC). The Fund invests in various sectors, including biotechnology and medical care; building material and construction; cement; chemical; communications and Internet; computer and peripheral equipment; electric and machinery; electronic parts and components; financial and insurance; foods; oil, gas and electricity; optoelectronic; plastics; semiconductor; shipping and transportation; textiles, and trading and consumers’ goods. The Fund’s investment advisor is JF International Management Inc.
A glance at Taiwan Fund Inc (NYSE:TWN)’s key stats reveals a current market capitalization of 320.5 Million based on 8.22 Million shares outstanding and a price at last close of $17.78 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2010-09-29, Skinner picked up 4,900 at a purchase price of $16.50. This brings their total holding to 4,900 as of the date of the filing.
On the sell side, the most recent transaction saw Skinner unload 4,900 shares at a sale price of $17.09. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Taiwan Fund Inc (NYSE:TWN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Kadmon Holdings Inc. (NYSE:KDMN) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kadmon Holdings Inc. (NYSE:KDMN) reported that Perceptive Advisors has picked up 5,185,847 of common stock as of 2017-03-17.
The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 5,185,847 representing a 10.00% stake in the company.
For those not familiar with the company, Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
A glance at Kadmon Holdings Inc. (NYSE:KDMN)’s key stats reveals a current market capitalization of 159.08 Million based on 45.08 Million shares outstanding and a price at last close of $3.57 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-13, Loeb picked up 1,488,095 at a purchase price of $3.36. This brings their total holding to 9,407,745 as of the date of the filing.
On the sell side, the most recent transaction saw Marquardt unload 5,852 shares at a sale price of $49.06. This brings their total holding to 76,184.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kadmon Holdings Inc. (NYSE:KDMN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sofinnova Venture Partners Picked Versartis Inc. (NASDAQ:VSAR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Versartis Inc. (NASDAQ:VSAR) reported that Sofinnova Venture Partners Viii, L.p. has picked up 1,658,865 of common stock as of 2017-03-17.
The acquisition brings the aggregate amount owned by Sofinnova Venture Partners Viii, L.p. to a total of 1,658,865 representing a 4.7% stake in the company.
For those not familiar with the company, Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.
A glance at Versartis Inc. (NASDAQ:VSAR)’s key stats reveals a current market capitalization of 646.60 Million based on 35.05 Million shares outstanding and a price at last close of $18.98 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-13, Perceptive picked up 59,133 at a purchase price of $15.51. This brings their total holding to 4,229,563 as of the date of the filing.
On the sell side, the most recent transaction saw Malik unload 103,122 shares at a sale price of $19.08. This brings their total holding to 2,105,228.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Versartis Inc. (NASDAQ:VSAR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.